Komori
Governance4570Immuno-Biological Laboratories Co.,Ltd.Pharmaceuticals

Independent Officer Notification Form

The company plans to newly elect 3 outside director candidates at the annual general meeting of shareholders, 2 of whom have been reported as independent officers. Including the 1 existing outside director, the company is expected to have a total of 4 outside directors.

Worth reading
33Immaterial
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
3
Number of new outside director candidates
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Controlling shareholder
TRANSGENIC GROUP INC.1.72%Voting rights

a major shareholder of the company, ranked third among shareholders, with a 1.72% shareholding). Whether it is a controlling shareholder or parent company, and its voting rights ratio: Not disclosed

When one company holds most of the voting rights, its wishes are more likely to prevail in management. How the interests of minority shareholders are protected is a key issue.

Number of directorsThe company has 4 outside directors, comprising 1 outside director who is not an Audit and Supervisory Committee member and 3 outside directors who are Audit and Supervisory Committee members. Total number of directors: Not disclosed
Number of independent officers4Number

This is the number of people reported to the exchange as independent officers. Whether someone is an outside officer and whether they qualify as independent are separate determinations.

Changes this time

With 25 June 2026 scheduled as the effective date of the change, the 3 individuals Okazumi Sadahiro (岡住貞宏), Kojima Ikkei (小嶋一慶) and Kojima Hirokazu (兒島宏和) are expected to become new outside directors. Okazumi Sadahiro (岡住貞宏) and Kojima Ikkei (小嶋一慶) will be designated as independent officers. Kojima Hirokazu (兒島宏和), who already meets the eligibility requirements, will also be designated as an independent officer.

Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
Number of directorsThe company has 4 outside directors, comprising 1 outside director who is not an Audit and Supervisory Committee member and 3 outside directors who are Audit and Supervisory Committee members. Total number of directors: Not disclosed
Number of independent officers4
Controlling shareholderTRANSGENIC GROUP INC. (a major shareholder of the company, ranked third among shareholders, with a 1.72% shareholding). Whether it is a controlling shareholder or parent company, and its voting rights ratio: Not disclosed
Changes this timeWith 25 June 2026 scheduled as the effective date of the change, the 3 individuals Okazumi Sadahiro (岡住貞宏), Kojima Ikkei (小嶋一慶) and Kojima Hirokazu (兒島宏和) are expected to become new outside directors. Okazumi Sadahiro (岡住貞宏) and Kojima Ikkei (小嶋一慶) will be designated as independent officers. Kojima Hirokazu (兒島宏和), who already meets the eligibility requirements, will also be designated as an independent officer.
Items this document does not state (3)
CommitteePolicy on cross-shareholdingsTakeover defenses

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because a proposal to elect outside officers will be submitted to the annual general meeting of shareholders. The candidates are expected to draw on their specialized knowledge in accounting, judicial scrivenship, administrative scrivenship, law and other fields, as well as their experience in corporate management, to identify issues, make recommendations and provide oversight.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Independent Officer Notification Form | Immuno-Biological Laboratories Co.,Ltd. (4570) timely disclosure | Komori